Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals announced findings from two new real-world evidence studies on SUBLOCADE® (extended-release buprenorphine) for opioid use disorder (OUD). The studies showed that adherence to monthly injectable buprenorphine is associated with a significantly lower relapse risk, fewer infection-related complications, and reduced healthcare utilization. Patients on SUBLOCADE were 3.5 to 8.1 times less likely to return to opioid use and experienced a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits compared to other MOUD treatments. These findings highlight the benefits of sustained treatment and the potential to reduce costly acute care crises.

Indivior Pharmaceuticals, Inc. announced the elimination of the Chief Scientific Officer position, effective June 1, 2026, leading to the termination of Dr. Christian Heidbreder's employment on December 31, 2026. Additionally, the company held its annual meeting of stockholders on May 13, 2026. Shareholders elected all eight director nominees, approved executive compensation on an advisory basis, and indicated a preference for annual Say-on-Pay votes. PricewaterhouseCoopers LLP US was also ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Indivior Pharmaceuticals, Inc. announced it has entered into a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC. This ASR is a component of the company's existing $400 million share repurchase program. Indivior made an upfront payment of $175 million and received an initial delivery of 3,717,473 shares, with final settlement anticipated by late June 2026. The company affirmed that the ASR is not expected to affect its previously issued financial guidance.

Indivior Pharmaceuticals, Inc. reported a significant increase in net revenue to $317 million and net income to $89 million for Q1 2026. The company completed its U.S. domestication in January 2026 and issued $500 million in Convertible Senior Notes due 2031, using proceeds to repay $333 million of prior debt, incurring an $18 million loss on extinguishment. The company also faces ongoing dental litigation with approximately 1,900 cases consolidated.

Indivior Pharmaceuticals, Inc. reported strong first-quarter 2026 financial results, with total net revenue increasing 19% year-over-year to $317 million and SUBLOCADE net revenue growing 32% to $232 million. The company achieved a record quarterly Adjusted EBITDA of $164 million, up 112% year-over-year, and subsequently raised its full-year 2026 financial guidance for both net revenue and Adjusted EBITDA. Additionally, Indivior repurchased $125 million in shares, completed a $500 million convertible senior notes offering to repay existing debt, and announced the discontinuation of internal development for two pipeline assets, INDV-6001 and INDV-2000.

Indivior Pharmaceuticals presented new scientific data at the ASAM Annual Conference, highlighting the effectiveness of its monthly injectable SUBLOCADE® for opioid use disorder (OUD). Studies showed SUBLOCADE significantly reduced the risk of non-fatal and fatal opioid overdoses compared to no treatment, with higher MOUD coverage leading to fewer overdose events. Provisional findings also indicated that OUD remission, defined by absence of DSM-5 symptoms, correlates with improved patient outcomes like lower craving and better quality of life. These findings reinforce the importance of sustained, evidence-based treatment and expand the body of evidence supporting SUBLOCADE's role in OUD recovery.

Indivior announced survey results published in the Journal of Correctional Health Care, indicating that correctional leaders view long-acting injectable (LAI) buprenorphine as a strategy to reduce diversion of medications for opioid use disorder (MOUD) in jails and prisons. The survey, funded by Indivior, found that 88% of jail and 87% of prison professionals believe LAI buprenorphine could help mitigate diversion. However, respondents also highlighted structural barriers to MOUD implementation, including inadequate staffing, limited coordination, cost, and access issues.